Modalis Therapeutics Partners With Ginkgo Bioworks, Enhancing Cell And Gene Therapy With CRISPR-GNDM Technology
Modalis Therapeutics Partners With Ginkgo Bioworks, Enhancing Cell And Gene Therapy With CRISPR-GNDM Technology
Modalis Joins Ginkgo's Technology Network
Modalis Therapeutics Corporation (Modalis) (Tokyo Stock Exchange: 4883) announced that it has entered into an agreement with Ginkgo Bioworks (Ginkgo) to join the Ginkgo Technology Network. This strategic alliance will enable Ginkgo's global customers in the cell and gene therapy fields to access Modalis' proprietary epigenome modulation technology, CRISPR-GNDM (Guide Nucleotide-Directed Modulation). Modalis' CRISPR-GNDM Technology is capable of activating or suppressing any gene in a controlled manner without requiring DNA cleavage. This collaboration also creates a significant opportunity for Modalis to establish additional strategic partnerships.
Modalis Joins Ginkgo's Technology Network
Modalis 加入 Ginkgo 的技術網絡
Modalis Therapeutics Corporation (Modalis) (Tokyo Stock Exchange: 4883) announced that it has entered into an agreement with Ginkgo Bioworks (Ginkgo) to join the Ginkgo Technology Network. This strategic alliance will enable Ginkgo's global customers in the cell and gene therapy fields to access Modalis' proprietary epigenome modulation technology, CRISPR-GNDM (Guide Nucleotide-Directed Modulation). Modalis' CRISPR-GNDM Technology is capable of activating or suppressing any gene in a controlled manner without requiring DNA cleavage. This collaboration also creates a significant opportunity for Modalis to establish additional strategic partnerships.
莫達利斯治療公司（Modalis）（東京證券交易所：4883）宣佈，它已與銀杏生物工程公司（Ginkgo）簽訂協議，加入銀杏科技網絡。該戰略聯盟將使Ginkgo在細胞和基因療法領域的全球客戶能夠獲得Modalis專有的表觀基因組調製技術CRISPR-GNDM（指導核苷酸定向調製）。莫達利斯的CRISPR-GNDM技術能夠以可控的方式激活或抑制任何基因，而無需進行DNA裂解。這種合作還爲Modalis建立更多戰略伙伴關係創造了重要機會。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧